US Stock Market Move | Snap (SNAP.US) surged over 13% as Q2 earnings exceeded expectations.
On Tuesday, Snap (SNAP.US) surged over 13%, closing at $5.72.
On Tuesday, Snap (SNAP.US) surged over 13%, reaching $5.72. In news, Snap released its second-quarter earnings report for the period ending June 30 after market hours on Monday Eastern Time. The data showed that the companys net loss significantly narrowed from $262.6 million in the same period last year to $164 million. Adjusted profits reached $250 million, well above the market expectation of $192 million.
During the period, Snap generated revenue of $1.6 billion, a year-on-year increase of 19%, which significantly exceeded Wall Street analysts' average expectation of $1.54 billion. Among this, advertising revenue, which accounted for most of the total revenue, grew by 9% year-on-year, reaching $1.28 billion. The Other Revenue category, including the Snapchat+ subscription service, grew by 85% year-on-year in the second quarter, reaching $316 million.
In terms of user data, Snap's global daily active users (DAU) reached 493 million in the quarter, an increase of about 5% year-on-year, maintaining the growth rate of the previous two quarters and surpassing the market expectation of 488 million.
Looking ahead, Snap provided a rather optimistic outlook: third-quarter revenue is expected to be between $1.7 billion and $1.74 billion, with the midpoint exceeding analysts' expectation of $1.7 billion; adjusted profits are forecasted to be between $300 million and $350 million, with the midpoint of $325 million slightly below the market expectation of $327 million.
Related Articles

CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.

RECOMMEND





